These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 27630329

  • 21. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR.
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [Abstract] [Full Text] [Related]

  • 22. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
    Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.
    Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
    [Abstract] [Full Text] [Related]

  • 23. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [Abstract] [Full Text] [Related]

  • 24. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD.
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A, Triptocare Study Group.
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [Abstract] [Full Text] [Related]

  • 26. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C, Kawachi M, Smith DD, Linehan J, Babilonia G, Mejia R, Wilson T, Smith SS.
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [Abstract] [Full Text] [Related]

  • 27. Two-stage classifiers that minimize PCA3 and the PSA proteolytic activity testing in the prediction of prostate cancer recurrence after radical prostatectomy.
    Jeske DR, Linehan JA, Wilson TG, Kawachi MH, Wittig K, Lamparska K, Amparo C, Mejia R, Lai F, Georganopoulou D, Smith SS.
    Can J Urol; 2017 Dec; 24(6):9089-9097. PubMed ID: 29260633
    [Abstract] [Full Text] [Related]

  • 28. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F.
    Carcinogenesis; 2017 Dec 07; 38(12):1180-1187. PubMed ID: 29029032
    [Abstract] [Full Text] [Related]

  • 29. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K, Wecker AL, Höflmayer D, Fraune C, Makrypidi-Fraune G, Hube-Magg C, Kluth M, Steurer S, Clauditz TS, Wilczak W, Simon R, Sauter G, Huland H, Heinzer H, Haese A, Schlomm T, Weidemann S, Luebke AM, Minner S, Bernreuther C, Bonk S, Marx A.
    Virchows Arch; 2020 Nov 07; 477(5):625-636. PubMed ID: 32417965
    [Abstract] [Full Text] [Related]

  • 30. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
    Väänänen RM, Ochoa NT, Boström PJ, Taimen P, Pettersson K.
    BMC Urol; 2015 Aug 21; 15():88. PubMed ID: 26294063
    [Abstract] [Full Text] [Related]

  • 31. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
    Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T.
    Oncol Rep; 2015 Sep 21; 34(3):1211-20. PubMed ID: 26134445
    [Abstract] [Full Text] [Related]

  • 32. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
    Filella X, Foj L.
    Int J Mol Sci; 2016 Oct 26; 17(11):. PubMed ID: 27792187
    [Abstract] [Full Text] [Related]

  • 33. PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
    Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.
    BMC Cancer; 2018 May 31; 18(1):612. PubMed ID: 29855276
    [Abstract] [Full Text] [Related]

  • 34. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W, Sun H, Meng F, Liu Z, Xiong J, Zhou S, Li F, Hu J, Hu Z, Liu Z.
    Int J Clin Exp Pathol; 2015 May 31; 8(2):1878-88. PubMed ID: 25973080
    [Abstract] [Full Text] [Related]

  • 35. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
    Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Lorente JA, Fumado L, Serrano L, Serrano S, Lloreta J, Hernández S.
    Prostate; 2015 Aug 01; 75(11):1216-26. PubMed ID: 25939480
    [Abstract] [Full Text] [Related]

  • 36. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
    Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, Kawachi MH, Crocitto LE, Wilson TG, Feng Z, Smith SS.
    Clin Chem; 2008 Dec 01; 54(12):2007-17. PubMed ID: 18948370
    [Abstract] [Full Text] [Related]

  • 37. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
    Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y.
    Tumour Biol; 2016 Sep 01; 37(9):12397-12402. PubMed ID: 27320318
    [Abstract] [Full Text] [Related]

  • 38. miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer.
    Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L, Seth A.
    Anticancer Res; 2011 Feb 01; 31(2):403-10. PubMed ID: 21378318
    [Abstract] [Full Text] [Related]

  • 39. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A, Alshalalfa M, Hegazy SA, Donnelly B, Bismar TA.
    Tumour Biol; 2016 Sep 01; 37(9):12287-12299. PubMed ID: 27271990
    [Abstract] [Full Text] [Related]

  • 40. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.
    Neoplasia; 2006 Oct 01; 8(10):885-8. PubMed ID: 17059688
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.